Document and Entity Information
Document and Entity Information | Jun. 10, 2021 |
Cover [Abstract] | |
Document Type | 8-K/A |
Document Period End Date | Jun. 10, 2021 |
Entity Registrant Name | Clovis Oncology, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-35347 |
Entity Tax Identification Number | 90-0475355 |
Entity Address, Address Line One | 5500 Flatiron Parkway |
Entity Address, Address Line Two | Suite 100 |
Entity Address, City or Town | Boulder |
Entity Address, State or Province | CO |
Entity Address, Postal Zip Code | 80301 |
City Area Code | 303 |
Local Phone Number | 625-5000 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock par Value $0.001 per Share |
Trading Symbol | CLVS |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Amendment Description | On June 10, 2021, Clovis Oncology, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”) to report the voting results for all proposals (other than Proposal Two) brought before the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was adjourned to June 23, 2021 solely with respect to Proposal Two. This Amendment No. 1 amends the Initial 8-K to disclose the voting results with respect to Proposal Two described under Item 5.07 below. |
Amendment Flag | true |
Entity Central Index Key | 0001466301 |